New steroid-sparing uveitis treatment gains orphan drug status

• Posted on: Jun 7 2019
• By: Saratoga Opthalmology
• Leave a response

The FDA granted orphan drug designation to a synthetic peptide for treatment of noninfectious intermediate, posterior, chronic anterior and panuveitis.
Source: AAO

Posted in: Uncategorized